COMPARISON
Icatibant vs Motixafortide
5 attributes held for at least one of the two. 5 differ. Each value carries the register it came from and the date that register was read.
Answer
Icatibant is authorised or registered in 10 and Motixafortide in 2 of the 10 registers read. Icatibant: highest phase Phase 3 (3 phase 3 trials, 0 with posted results). Motixafortide: highest phase Phase 3 (1 phase 3 trial, 0 with posted results). 0 registered trials include both.
States no view on which is preferable, safer or more effective. Not medical advice.
| Icatibant | Motixafortide | |
|---|---|---|
| Registered trials differs | 37 clinicaltrials.gov · 2026-10-03 | 11 clinicaltrials.gov · 2026-10-03 |
| FDA label differs | FDA-approved: SAJAZIR openfda · 2026-10-03T17:23:44.062Z | FDA-approved: APHEXDA openfda · 2026-10-03T17:23:44.062Z |
| EU authorisation differs | Authorised ema · 2026-10-03 | Nothing on record ema read 2026-08-31 |
| EU authorised on differs | 2008-07-11 ema · 2026-10-03 | Not checked no record of "authorisedOn" for motixafortide |
| ATC code differs | B06AC02 ema · 2026-10-03 | Not checked no record of "atcCode" for motixafortide |
SIDE EFFECTS
Most common side effects, each beside its own placebo
| Side effect | Icatibant | placebo | Motixafortide | placebo |
|---|---|---|---|---|
| Hereditary angioedema | 18.1% | 18.7% | - | - |
| Headache | 10.1% | 6.7% | - | - |
| Leukocytosis | - | - | 98.6% | 0.0% |
| Injection site pain | - | - | 93.2% | 27.8% |
| Injection site erythema | - | - | 78.1% | 11.1% |
| Pruritus | - | - | 61.6% | 0.0% |
| Urticaria | - | - | 49.3% | 0.0% |
| Injection site pruritus | - | - | 46.6% | 8.3% |
| Flushing | - | - | 42.5% | 0.0% |
| Injection site induration | - | - | 37.0% | 13.9% |
| Feeling hot | - | - | 35.6% | 0.0% |
| Paraesthesia | - | - | 27.4% | 0.0% |
Trial register Icatibant: 4 placebo-controlled trials; Motixafortide: 1. Each peptide is compared with placebo in its own trials, not with the other: a dash means the event is not in that peptide's top list. Icatibant side effects · Motixafortide side effects
LEGAL STATUS
Approval in each country read
| Country | Icatibant | Motixafortide | Register |
|---|---|---|---|
| United States | FDA-approved | FDA-approved | Regulator FDA |
| European Union | Authorised | Not on the register | Regulator EMA |
| United Kingdom | Authorised | Not on the register | Regulator MHRA |
| Canada | Authorised | Not on the register | Regulator Health Canada |
| Australia | Registered | Status unknown | Regulator TGA |
| Switzerland | Authorised | Not on the register | Regulator Swissmedic |
| Brazil | Registado | Not on the register | Regulator ANVISA |
| Serbia | Authorised | Not on the register | Regulator ALIMS |
| Singapore | Registered | Registered | Regulator HSA |
| Turkey | Ruhsatli | Not on the register | Regulator TITCK |
Values reproduce public registers on the dates shown. This comparison states no view on which compound is preferable, safer or more effective. Not medical, legal or regulatory advice.
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.